• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Willingness to pay and accept risks to cure chronic disease.为治愈慢性病而支付费用和承担风险的意愿。
Am J Public Health. 1986 Apr;76(4):392-6. doi: 10.2105/ajph.76.4.392.
2
Feasibility of willingness-to-pay measurement in chronic arthritis.慢性关节炎中支付意愿测量的可行性
Med Decis Making. 1984;4(2):195-215. doi: 10.1177/0272989X8400400207.
3
Valuing a hypothetical cure for rheumatoid arthritis using the contingent valuation methodology: the patient perspective.使用条件价值评估法评估类风湿关节炎的假设性治愈方法:患者视角
J Rheumatol. 2005 Mar;32(3):443-53.
4
Willingness to pay for improvement of physical function among rheumatoid arthritis patients as measured by Health Assessment Questionnaire.健康评估问卷测量的类风湿关节炎患者对改善身体功能的支付意愿。
Rheumatol Int. 2011 Mar;31(3):347-52. doi: 10.1007/s00296-009-1280-1. Epub 2009 Dec 18.
5
Willingness to pay: a valid and reliable measure of health state preference?支付意愿:健康状态偏好的有效且可靠的衡量指标?
Med Decis Making. 1994 Jul-Sep;14(3):289-97. doi: 10.1177/0272989X9401400311.
6
Auranofin in the treatment of rheumatoid arthritis. A two-year study.金诺芬治疗类风湿关节炎。一项为期两年的研究。
Mo Med. 1985 Nov;82(11):711-5.
7
Reliability of self-reported willingness-to-pay and annual income in patients treated for toenail onychomycosis.接受趾甲甲真菌病治疗患者自我报告的支付意愿和年收入的可靠性。
Br J Dermatol. 2007 May;156(5):922-8. doi: 10.1111/j.1365-2133.2006.07740.x.
8
A double-blind study comparing sodium aurothiomalate and auranofin in patients with rheumatoid arthritis previously stabilized on sodium aurothiomalate.一项双盲研究,比较金硫代苹果酸钠和金诺芬对之前已使用金硫代苹果酸钠病情稳定的类风湿关节炎患者的疗效。
Int J Clin Pharmacol Res. 1984;4(6):395-401.
9
Radiographic evaluation of erosion in rheumatoid arthritis: double blind study of auranofin vs placebo.类风湿性关节炎中侵蚀的影像学评估:金诺芬与安慰剂的双盲研究
J Rheumatol. 1984 Dec;11(6):768-71.
10
Feasibility and construct validity of the parent willingness-to-pay technique for children with juvenile idiopathic arthritis.父母意愿支付法在幼年特发性关节炎患儿中的可行性及结构效度
Arthritis Rheum. 2004 Dec 15;51(6):899-908. doi: 10.1002/art.20829.

引用本文的文献

1
Measuring Patient Preferences to Inform Clinical Trial Design: An Example in Rheumatoid Arthritis.衡量患者偏好以指导临床试验设计:类风湿关节炎的一个实例
Patient. 2025 Mar;18(2):161-171. doi: 10.1007/s40271-024-00724-4. Epub 2024 Dec 12.
2
Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness-to-Pay Approach.采用意愿支付法评估英夫利昔单抗治疗强直性脊柱炎的价值。
Arthritis Care Res (Hoboken). 2018 Apr;70(4):608-616. doi: 10.1002/acr.23299. Epub 2018 Feb 18.
3
Time Trade-Off as a Measure of Health-Related Quality of Life: Long Bone Nonunions Have a Devastating Impact.作为健康相关生活质量衡量指标的时间权衡法:长骨骨不连具有毁灭性影响。
J Bone Joint Surg Am. 2015 Sep 2;97(17):1406-10. doi: 10.2106/JBJS.N.01090.
4
Estimating burden and disease costs of exposure to endocrine-disrupting chemicals in the European union.估算欧盟内分泌干扰化学物暴露的负担及疾病成本。
J Clin Endocrinol Metab. 2015 Apr;100(4):1245-55. doi: 10.1210/jc.2014-4324. Epub 2015 Mar 5.
5
Precision medicine in chronic disease management: The multiple sclerosis BioScreen.慢性病管理中的精准医学:多发性硬化症生物筛查。
Ann Neurol. 2014 Nov;76(5):633-42. doi: 10.1002/ana.24282. Epub 2014 Oct 14.
6
Quantifying the economic burden of malaria in Nigeria using the willingness to pay approach.采用支付意愿法量化尼日利亚疟疾的经济负担。
Cost Eff Resour Alloc. 2007 May 22;5:6. doi: 10.1186/1478-7547-5-6.
7
Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis.第一代抗组胺药治疗变应性鼻炎的成本效益分析。
Pharmacoeconomics. 2004;22(14):929-42. doi: 10.2165/00019053-200422140-00003.
8
The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach.轻度至中度痴呆症中胆碱酯酶抑制剂的成本效益:一种支付意愿方法。
CNS Drugs. 2003;17(14):1045-57. doi: 10.2165/00023210-200317140-00004.
9
Quality of life in children and adolescents with cystic fibrosis: implications for optimizing treatments and clinical trial design.患有囊性纤维化的儿童和青少年的生活质量:对优化治疗和临床试验设计的启示。
Paediatr Drugs. 2003;5(1):41-56. doi: 10.2165/00128072-200305010-00004.
10
Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals.通过评定量表、时间权衡法和标准博弈法测量的效用:给医疗保健专业人员的综述与参考
J Epidemiol. 2002 Mar;12(2):160-78. doi: 10.2188/jea.12.160.

本文引用的文献

1
Mental illness and the economic value of a man.精神疾病与男性的经济价值
Ment Hyg. 1950 Oct;34(4):582-91.
2
Theoretical considerations on the cost of illness.关于疾病成本的理论思考。
J Health Econ. 1983 Aug;2(2):149-59. doi: 10.1016/0167-6296(83)90004-8.
3
The framing of decisions and the psychology of choice.决策的框架与选择的心理学。
Science. 1981 Jan 30;211(4481):453-8. doi: 10.1126/science.7455683.
4
The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis.癌症、机动车伤害、冠心病和中风的发病率及经济成本:一项比较分析。
Am J Public Health. 1980 Dec;70(12):1249-60. doi: 10.2105/ajph.70.12.1249.
5
Measurement of patient outcome in arthritis.关节炎患者预后的测量
Arthritis Rheum. 1980 Feb;23(2):137-45. doi: 10.1002/art.1780230202.
6
Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer.言语与生存:喉癌患者生活质量与数量的权衡
N Engl J Med. 1981 Oct 22;305(17):982-7. doi: 10.1056/NEJM198110223051704.
7
On the elicitation of preferences for alternative therapies.关于替代疗法偏好的引出。
N Engl J Med. 1982 May 27;306(21):1259-62. doi: 10.1056/NEJM198205273062103.
8
Cost-of-illness methodology: a guide to current practices and procedures.疾病成本法:当前实践与程序指南
Milbank Mem Fund Q Health Soc. 1982 Summer;60(3):429-62.
9
The economic value of life: linking theory to practice.生命的经济价值:理论与实践的联系
Am J Public Health. 1982 Jun;72(6):555-66. doi: 10.2105/ajph.72.6.555.
10
The value of human life revisited.重探人类生命的价值。
Am J Public Health. 1982 Jun;72(6):536-8. doi: 10.2105/ajph.72.6.536.

为治愈慢性病而支付费用和承担风险的意愿。

Willingness to pay and accept risks to cure chronic disease.

作者信息

Thompson M S

出版信息

Am J Public Health. 1986 Apr;76(4):392-6. doi: 10.2105/ajph.76.4.392.

DOI:10.2105/ajph.76.4.392
PMID:3082226
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1646507/
Abstract

Measurements of disease burden focus most often on economic outputs--neglecting effects on quality of life. More comprehensive quantification is based on what people would pay or risk to avoid illness. Many, however, find it difficult to respond thoughtfully to hypothetical questions about what they would pay or risk. With response rates frequently under 50 per cent, the practicality of these methods has been of concern. In this study, specially trained interviewers asked 247 subjects with rheumatoid arthritis how much of their income they would pay and how large a mortal risk they would accept to achieve a hypothetical cure. Ninety-eight per cent of the subjects estimated their maximum acceptable risk (MAR) at an average 27 per cent chance of immediate death. Eighty-four per cent gave plausible responses to the willingness-to-pay (WTP) questions, with a mean WTP of 22 per cent of household income. The aspect of disease most strongly associated with WTP was impairment in activities of daily living; measured pain was most associated with MAR. The response rates achieved indicate the overall feasibility of these methods; the associations of WTP and MAR with other variables suggest systematic consideration of personal circumstances.

摘要

疾病负担的衡量通常侧重于经济产出,而忽视了对生活质量的影响。更全面的量化是基于人们为避免疾病愿意支付的费用或愿意承担的风险。然而,许多人发现很难认真回答关于他们愿意支付多少费用或承担何种风险的假设性问题。由于回答率经常低于50%,这些方法的实用性一直受到关注。在这项研究中,经过专门培训的访谈者询问了247名类风湿性关节炎患者,为了实现一种假设的治愈,他们愿意支付多少收入以及愿意接受多大的死亡风险。98%的受试者估计他们的最大可接受风险(MAR)平均为立即死亡的几率27%。84%的受试者对支付意愿(WTP)问题给出了合理的回答,平均支付意愿为家庭收入的22%。与支付意愿最密切相关的疾病方面是日常生活活动受损;测量出的疼痛与最大可接受风险最相关。所达到的回答率表明了这些方法的总体可行性;支付意愿和最大可接受风险与其他变量的关联表明了对个人情况的系统考虑。